Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6279935 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5479042 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6927973 | 0.98 | SMN1; SMN2 (0.53) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6574395 | 0.98 | SMN1; SMN2 (0.53) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6574385 | 0.98 | SMN1; SMN2 (0.53) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25005917 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28927446 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30273373 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28639757 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6372735 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257593-A1 | CHIRAL MULTIDENTATE LIGAND AND USE THEREOF IN ASYMMETRIC HYDROGENATION | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023077643-A1 | CHIRAL MULTIDENTATE LIGAND AND USE THEREOF IN ASYMMETRIC HYDROGENATION | 凯特立斯（深圳）科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-20230124576-A1 | CHIRAL MULTIDENTATE LIGAND, AND APPLICATION THEREOF IN ASYMMETRIC HYDROGENATION | SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20040265991-A1 | Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives | KANEKA CORPORATION (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1454899-A1 | PROCESS FOR PREPARATION OF (S)-ALPHA-HALOME THYLPYRIDINE METHANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124576-A1 | CHIRAL MULTIDENTATE LIGAND, AND APPLICATION THEREOF IN ASYMMETRIC HYDROGENATION | H1-4, CHRM1, CHRM2 | SMN1; SMN2 4307/4885CFTR 4873/4885SLC6A2 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.